/ Print /

ASH 2016

ASH 2016

Family history, genetics play growing role in leukemia screeningInherited susceptibilities to leukemias are becoming better understood and have important implications for screening, prevention, genetic counseling, and treatment.
Gene therapy could be ‘ultimate solution’ for sickle cell diseaseInvestigational gene therapies might reduce the suffering and death caused by this genetic disease.
Large variety of multiple myeloma treatment options presents challengesThere now exist numerous treatment options for multiple myeloma but how best to sequence them is still under study
Top barriers to fully utilizing precision medicine biomarkersAs development of molecular biomarkers hastens, administrators, clinicians and regulators are working to organize and define biomarkers’ appropriate roles in clinical care—and discussing how to efficiently share the massive amounts of genomic data that will result.
Promising treatment developments in lymphoma immunotherapiesIn this Q&A, a physician and lymphoma expert discusses treatment advances and promising signs for the future.
Top problems with EHRs and emerging risks jeopardize care qualityAn ASH presenter describes how better health IT and better institutional practices are necessary to leverage EHRs for quality of care.
Novel immunotherapies for leukemia could raise life-threatening syndromeNovel immunotherapy treatments are showing promise for patients with acute lymphoblastic leukemia (ALL), but they can trigger cytokine release syndrome.
Hodgkin lymphoma: First hematologic cancer cured with immunotherapy?Immune checkpoint inhibitors are taking the stage in treating relapsed and refractory Hodgkin lymphoma. Read more.
Top 10 sessions to attend at ASH 2016This year’s American Society of Hematology (ASH) Conference, held in San Diego, will feature a wide array of sessions.